Share on StockTwits

Veracyte (NASDAQ:VCYT) Director Evan/ Fa Jones sold 23,882 shares of the stock in a transaction dated Friday, May 30th. The stock was sold at an average price of $15.33, for a total value of $366,111.06. The sale was disclosed in a document filed with the SEC, which is available at this link.

Several analysts have recently commented on the stock. Analysts at Cowen and Company raised their price target on shares of Veracyte from $17.00 to $22.00 in a research note on Wednesday, March 19th. They now have an “outperform” rating on the stock. Analysts at Leerink Swann raised their price target on shares of Veracyte from $21.00 to $23.00 in a research note on Wednesday, March 19th.

Veracyte (NASDAQ:VCYT) traded down 4.01% on Monday, hitting $14.61. The stock had a trading volume of 18,538 shares. Veracyte has a one year low of $10.88 and a one year high of $19.00. The stock has a 50-day moving average of $13.47 and a 200-day moving average of $14.63. The company’s market cap is $309.3 million.

Veracyte (NASDAQ:VCYT) last released its earnings data on Thursday, May 8th. The company reported ($0.32) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.31) by $0.01. The company had revenue of $7.50 million for the quarter, compared to the consensus estimate of $7.19 million. During the same quarter last year, the company posted ($9.04) earnings per share. Veracyte’s revenue was up 70.5% compared to the same quarter last year. Analysts expect that Veracyte will post $-1.32 EPS for the current fiscal year.

Veracyte, Inc is a diagnostics company focused on molecular cytology. The Company focuses on diseases that often require invasive procedures for an accurate diagnosis.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.